- Home
- Companies
- Beta Bionics, Inc.
- News
- Beta Bionics Receives FDA Breakthrough ...
Beta Bionics Receives FDA Breakthrough Device Designation for the iLet Bionic Pancreas System
Source: Beta Bionics, Inc.
Boston, MA -July 1, 2019 - Beta Bionics, Inc. — a medical technology company leveraging lifelong autonomous learning to develop and commercialize the world's first fully automated bionic pancreas — today announced that the company has completed a S63 million Series B2 equity financing. This follows six months after the final close of another $63 million equity financing and brings the total combined Series B and B2 financings to just over $126 million. Beta Bionics, Inc. announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its investigational iLet Bionic Pancreas System.
-
Most popular related searches
Customer comments
No comments were found for Beta Bionics Receives FDA Breakthrough Device Designation for the iLet Bionic Pancreas System. Be the first to comment!